Notice of Clarification Regarding Letters of Collaboration in RFA-DA-15-006 "Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2)"

Notice Number: NOT-DA-14-030

Key Dates
Release Date: August 22, 2014

Related Announcements
RFA-DA-15-006

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

This Notice is to clarify that letters of collaboration are allowed in RFA-DA-15-006"Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) ."

Part 2., Section IV., 2. Content and Form of Application Package, SF424 (R&R) Cover

Current language:
Cover Letter: Provide names and affilications of significant collaborators for the Avenir Award project. Letters of collaboration and biosketches of collaborators are not allowed.

Revised language:
Cover Letter: Provide names and affilications of significant collaborators for the Avenir Award project. Letters of collaboration are allowed. Biosketches of collaborators are not allowed.

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1309
Email: jpollock@mail.nih.gov